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Objective: Synovitis is evident in a substantial subpopulation of patients with osteoarthritis (OA) and is
associated with development of pathophysiology. Recently we have shown that adipose-derived stem
cells (ASC) inhibit joint destruction in collagenase-induced experimental OA (CIOA). In the current study
we explored the role of synovitis and alarmins S100A8/A9 in the immunomodulatory capacity of ASCs in
experimental OA.
Method: CIOA, characterized by synovitis, and surgical DMM (destabilization of medial meniscus) OA
were treated locally with ASCs. Synovial activation, cartilage damage and osteophyte size were measured
on histological sections. Cytokines in synovial washouts and serum were determined using Luminex or
enzyme-linked immunosorbent assay (S100A8/A9), mRNA levels with reverse-transcriptase (RT)-qPCR.
Results: Local administration of ASCs at various time-points (days 7 or 14) after DMM induction had no
effect on OA pathology. At day 7 of CIOA, already 6 h after ASC injection mRNA expression of pro-
inﬂammatory mediators S100A8/A9, interleukin-1beta (IL-1b) and KC was down-regulated in the
synovium. IL-1b protein, although low, was down-regulated by ASC-treatment of CIOA. S100A8/A9
protein levels were very high at 6 and 48 h and were decreased by ASC-treatment. The protective action
of ASC treatment in CIOA was only found when high synovial inﬂammation was present at the time of
deposition which was reﬂected by high serum S100A8/A9 levels. Finally, successful treatment resulted in
signiﬁcantly lower levels of serum S100A8/A9.
Conclusion: Our study indicates that synovial activation rapidly drives anti-inﬂammatory and protective
effects of intra-articularly deposited ASCs in experimental OA which is reﬂected by decreased S100A8/A9
levels.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is primarily a disease of the cartilage. How-
ever, synovitis is thought to contribute to aggravation of joint pa-
thologyaswell1,2. Up to 50%ofOApatientshave synovitis,whichwas
demonstratedbymagnetic resonance imaging, ultrasonographyand
arthroscopy3e5. Histologically, inﬂammation in the synovialo: P.L.E.M. van Lent, Experi-
Radboud University Medical
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ternational. Published by Elsevier Lmembrane is characterized by high levels of CD68þmacrophages
expressing an activated phenotype and presence of pro-
inﬂammatory cytokines like IL-1b and TNFa3,6,7.
Synovial lining macrophages contribute to joint destruction in
murine collagenase-induced osteoarthritis (CIOA). When lining
macrophageswere selectively depleted from amouse knee joint prior
to induction of CIOA, a strongly diminished thickening of the syno-
vium was observed which coincided with inhibition of cartilage
degradation and formation of cartilage/bone within ligaments8. Sy-
novial macrophages produce both catabolic and anabolic factors that
contribute to degradation and new formation of cartilage9. Major
catabolic factors produced by activated macrophages are alarmins or
damage associated molecular patterns (DAMPs) S100A8 andtd. All rights reserved.
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vium of OA patients and we recently showed that S100A8/A9 predict
development of cartilage destruction in the Dutch CHECK cohort of
early symptomatic OA patients and have catabolic effects on OA
chondrocytes via Toll-like receptor (TLR)-411,12.
Mesenchymal stem cells (MSCs) have been shown to exhibit
immunosuppressive characteristics13,14, next to their effect on tissue
speciﬁc differentiation15. MSCs can secrete multiple immunosup-
pressive factors, like IL-10, IL-1 Receptor Antagonist (IL-1RA), Indo-
leamine 2,3-DiOxygenase (IDO), TGFb and ProstaGlandin E2 (PGE2)16
and they can induce anti-inﬂammatory effects in macrophages17,18.
Moreover, evidence is gathering that MSCs need an inﬂammatory
milieu to deliver immunosuppressive signals13,19,20. Next to bone
marrow, adipose tissue also hosts multipotent stem cells. These
adipose-derived stem cells (ASCs) share multiple properties with
bonemarrow-derived MSCs21, but are more accessible and abundant
(5% vs 0.0001e0.001%of nucleated cells). Both types have adipogenic,
osteogenic and chondrogenic differentiation potential and display
immunosuppressive properties in vitro as well as in vivo22.
Recently, we described that local administration of ASCs in the
knee joint in early stage CIOA inhibited synovial activation and
largely protected against new cartilage/bone formation within
collateral and cruciate ligaments23. Furthermore, cartilage damage
was reduced in various layers of the knee joint. We localized GFP-
labeled ASCs within the synovial lining layer in close contact to
synovial macrophages23. The immunosuppressive capacity of the
ASCs may thereby be stimulated by the pro-inﬂammatory cyto-
kines released by macrophages during the early phase of CIOA.
In the present study we investigated whether the suppressive
effect of ASCs on experimental induced OA is driven by synovitis.
Furthermore, we explored the role of S100A8/A9, major products
during synovitis, in this anti-inﬂammatory effect of ASCs.
Materials and methods
Animals
A total of 120 C57BL6J mice were obtained from Janvier. Animals
weremale and between 12 and 14weeks old (averageweight 24.5 g
SD 0.3), housed in ﬁlter-top cages with up to 10 animals per cage
and received a standard diet and tap water ad libitum.
Induction of experimental OA
We used two different models of experimental OA, CIOA and
DMM, because they differ in synovial inﬂammation. Experimental
CIOA (which has relatively high synovial inﬂammation) was
induced as previously described24. Brieﬂy, right knee joints of mice
were injected with 1 U collagenase type VII from Clostridium his-
tolyticum (SigmaeAldrich) at day 0 and day 2, causing disruption of
the ligaments and local instability of the knee joint. To achieve a
CIOA with less synovial activation, only one time 1 U collagenase
was injected. Experimental DMM OA (destabilized medial
meniscus, a model where synovial activation is scant) was induced
by transection of the medial anterior meniscotibial ligament25.
For the DMM-study eight mice/groupwere used on day 7 and 10
mice/group for day 14. For the effects of ASCs on synovium in CIOA,
six mice/group were used on day 2, 14 and 42, eight mice/group
after 6 h. For the comparison between high and low synovial
activation in CIOA, eight mice/group were used.
Adipose stem cells
ASCswere isolated from adipose tissue surrounding the inguinal
lymph nodes of mice and cultured for 2 weeks according tostandard procedures in DMEM/F12 (Gibco) supplemented with 1%
penicillin/streptomycin (Invitrogen), 0.5% amphotericin B (Invi-
trogen), 16 mM biotin (SigmaeAldrich), 18 mM pantothenic acid
(SigmaeAldrich), 100 mM ascorbic acid (SigmaeAldrich). ASCs
stained positive for Sca-1, CD44 and CD105 (BD Bioscience; Bio-
legend and eBioscience) and negative for CD11b, cKit and CD34
(Biolegend; BD Bioscience and eBioscience). 20.000 cells in 6 mL
mouse serum (Jackson Immunoresearch) with 4% mouse albumin
(SigmaeAldrich) were injected intra-articularly into the knee joint.
Control animals were injected with only mouse serum containing
4% mouse albumin.
Isolation of murine synovial specimens
At various time points (6 h, 2, 14 and 42 days) after induction of
OA, synovial specimens were isolated as described previously11.
Brieﬂy, joint capsule specimens were isolated on the medial and
lateral sides of the patella with a biopsy punch. Synovial specimens
were snapfrozen in liquid nitrogen and stored for RNA isolation.
In vitro cross-talk between adipose stem cells and activated
macrophages
ASCs (passage 2) were stimulated for 24 h with 10 ng/ml IFNg
and IL-1b and 1 mg/ml recombinant murine S100A8. Bone marrow
cells were harvested from C57Bl6J mice and 1  106 were differ-
entiated into macrophages with M-CSF for 6 days and activated
with 10 ng/ml LPS for 24 h. Consequently, these macrophages were
incubated for 24 h with IFNg- and IL-1b- stimulated ASC super-
natant. Effect on gene expression of suppressive factors in both
ASCs and macrophages was investigated using reverse transcrip-
tion (RT)-qPCR.
Preparation of RNA and RTeqPCR
RNA from murine synovium was isolated by ﬁrst disrupting
synovial tissue with the MagNA Lyser (Roche) 5 times for 20 s and
then isolating the RNA using the RNeasy-kit (Qiagen) according to
the manufacturers protocol. RNA from cultured ASCs and macro-
phages was isolated using TRI-reagent (SigmaeAldrich). RNA was
reverse transcribed to cDNA and qPCR was performed with speciﬁc
primers and the SYBR Green Master mix in the ABI Prism 7000
Sequence Detection System (Applied Biosystems/Life Technolo-
gies). Expression levels were normalized to GAPDH. Primer se-
quences were designed on exoneexon transition of murine genes
and can be found in Table I.
Histological analysis of OA progression
Knee joints were dissected and ﬁxed in 4% formalin. After ﬁx-
ation, joints were decalciﬁed in 4% formic acid buffered in PBS and
processed for histology.
Parafﬁn embedded knee joints were cut in sections of 7 mm,
stained with Safranin O (Saf-O) and counterstained with Fast Green
for analysis of cartilage damage and chondrophyte/osteophyte
associated ligaments (collateral/cruciate). Cartilage damage was
scored blinded using a modiﬁed form of the Pritzker Osteoarthritis
Research Society International (OARSI) OA score, which takes into
account the grading and staging components26. Five sections for
each specimen were evaluated by two blinded investigators. Min-
imal score is 0, indicating no cartilage pathology whatsoever,
whereas 30 is the maximum score, indicating highest grade (6) and
stage (5). For scoring of synovial activation, Hematoxylin Eosin (HE)
staining was used. Synovial thickening/activation was scored using
an arbitrary score from 0 to 3 as previous described27. Saf-O stained
Table I
Primers used for RT-qPCR
Gene Forward primer Reverse primer
Arginase GAAAGTTCCCAGATGTACCAGGAT CGATGTCTTTGGCAGATATGCA
IDO CAAAGCAATCCCCACTGTATCC CTATGTCGTGCAGTGCCTTTTC
IL-1b GGACAGAATATCAACCAACAAGTGATA GTGTGCCGTCTTTCATTACACAG
IL-1RA CAAGATGCAAGCCTTCAGAATCT CACCATGTCTATCTTTTCTTCTAGTTTGA
IL-6 CAAGTCGGAGGCTTAATTACACATG ATTGCCATTGCACAACTCTTTTCT
IL-10 ATTTGAATTCCCTGGGTGAGAA ACACCTTGGTCTTGGAGCTTATTAA
iNOS CGTTTCGGGATCTGAATGTGA GGGCAGCCTGTGAGACCTT
KC (CXCL1) TGGCTGGGATTCACCTCAA GAGTGTGGCTATGACTTCGGTTT
S100A8 TGTCCTCAGTTTGTGCAGAATATAAAT TTTATCACCATCGCAAGGAACTC
S100A9 GGCAAAGGCTGTGGGAAGT CCATTGAGTAAGCCATTCCCTTTA
TGF-b1 GCAGTGGCTGAACCAAGGA AAGAGCAGTGAGCGCTGAATC
Primer sequences for target genes for RT-qPCR spanned exoneexon transitions of murine genes. IDO ¼ indoleamine 2,3-dioxygenase,
IL ¼ interleukin, RA ¼ receptor antagonist, iNOS ¼ inducible nitric oxide synthase, TGF ¼ transforming growth factor.
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phytes using an image analysis system (Leica Application Suite,
Leica).
Measurement of S100A8/A9 in the serum of mice with experimental
OA
S100A8/A9 concentrations were determined in synovial wash-
outs of murine knee joints by a sandwich enzyme-linked immu-
nosorbent assay (ELISA) speciﬁcally for murine S100A8/A9 as
described previously28.
Measurement of TGFb-activity
TGFb-activity was determined by adding 1:5 dilution of synovial
washouts overnight to 3T3 ﬁbroblasts transduced with adenoviral
CAGA-luciferase (CAGA-luc) with a multiplicity of infection (MOI)
of 10 (10 plaque-forming units) per cell, after which luminescence
was measured. The plasmid was kindly provided by Dr. Ten Dijke
(Department of Molecular Cell Biology, Leiden University Medical
Center, The Netherlands). The CAGA-boxes in the vector are tran-
scribed by Smad3/4 through active TGFb, resulting in luciferase
activity29.
Ethical considerations
All animal experiments were approved by the local authority
Animal Care and Use Committee and local ethics committee of the
Radboud university medical center (RU-DEC 2011-101/2012-247)
and were performed by personnel certiﬁed by the Dutch Ministry
of WVC.
Statistical analysis
Data were statistically evaluated using the ManneWhitney U
test or Student t test using Graph Pad Prism 5 (GraphPad Software).
Differences were called signiﬁcant with P-value <0.05 (*), <0.01 (**)
or <0.0005 (***).
Results
ASC treatment has no effect on development of joint destruction in
DMM experimental OA with low synovial activation
In a previous study we found that a single injection of ASCs into
a mouse knee joint of CIOA inhibited development of cartilage
destruction, chondrogenesis in ligaments and osteophyte forma-
tion23. CIOA is characterized by thickening and activation of thesynovial layer containing activated macrophages. To investigate
further whether synovial macrophage activation may drive the
anti-inﬂammatory activity of ASCs, ASCs were tested in the DMM
model, in which synovial macrophage activation is scant11. A single
injection of 20.000 ASCswas given into the right knee joint either at
day 7 or day 14 [Fig. 1] or days 14 and 21 (data not shown) after
induction of DMM. In contrast to CIOA, no effect of ASC treatment
was found in DMM on cartilage destruction, osteophyte formation
or chondrogenesis in ligaments. These results suggest that the
healing capacity of ASC is related to synovitis.Intra-articularly applied ASCs rapidly suppress the activation status
of the synovial lining layer during CIOA
To investigate the effect of the intra-articularly injected ASCs on
the inﬂammatory status of the synovium, we injected 20.000 ASCs
in the knee joint at day 7 after induction of CIOA and subsequently
isolated synovium 6 h, 2, 14 and 42 days thereafter. Various
macrophage derived cytokines (IL-1b, IL-6, TNFa, IL-10, KC, S100A8,
S100A9) were measured using RT-quantitative polymerase chain
reaction (qPCR). Pro-inﬂammatory mediators S100A8, S100A9, IL-
1b, IL-6 and KCwere highest 6 h after control injection and declined
later on, which is in line with earlier studies showing highest sy-
novial activation in early stages of CIOA11. Interestingly, ASCs
signiﬁcantly downregulated S100A8, S100A9 [Fig. 2(A)], IL-1b and
KCmRNA [Fig. 2(B)] already 6 h after ASC injection. AlthoughmRNA
levels were still lower at day 14, this did not reach signiﬁcance. IL-6
mRNA levels were signiﬁcantly reduced at day 14, and lower at day
2, although not signiﬁcantly [Fig. 2(B)]. In addition, protein levels of
various cytokines (IL-1b, IL-6, IL-10, KC, IFNg) and S100A8/A9 were
measured in synovial washouts using Luminex or ELISA (for
S100A8/A9). Low levels of IL-1b [Fig. 3(B)] and very high levels of
S100A8/A9 [Fig. 3(A)] were detected 6 h and 2 days after ASC or
control injection. IL-1b protein levels were found to be lower at day
2, 14 and 42 after ASC treatment (44, 45 and 34% lower, respec-
tively) [Fig. 3(B)]. Moreover, S100A8/A9 was signiﬁcantly down-
regulated on protein level 6 and 48 h after ASC injection (48 and
58% lower, respectively) [Fig. 3(A)]. No effect of ASC treatment was
found on protein levels of IL-6 and KC [Fig. 3(B)]. These results
indicate that the suppressive effect by ASCs is rapidly initiated in
the synovium. Apart from lowering catabolic cytokines, ASC treat-
ment may also affect anabolic growth factors like TGFb and BMP-2,
crucial during osteophytosis30. However, no effect of ASCs was
found on mRNA levels of TGFb and BMP-2 (data not shown).
Measuring TGFb activity in synovial washouts using a CAGA-luc
assay, no differences were found at 6 h, 2, 14 or 42 days after ASC
and control treatment [Fig. 3(C)].
Fig. 1. ASC treatment has no effect on development of joint destruction in a DMM model in which synovial activation is scant. DMM OA was induced by transection of the medial
anterior meniscotibial ligament and 20.000 ASCs were injected intra-articularly at day 7 or 14. Mice were sacriﬁced at day 56 and whole knee joints were prepared for histology. A.
No difference was found on mean cartilage damage as assessed by the modiﬁed Pritzker OARSI score. B. Injection of ASCs on neither day 7 or 14 changed osteophyte size as
measured at the margins of the medial femur and tibia by image analysis software. C. Similarly, chondrogenic area in cruciate and medial collateral ligaments was not changed by
ASC injection at day 7 or 14 of DMM, measured by redness in Safranin-O stained sections. N ¼ 8 mice/group in experiment with ASC injection at day 7, n ¼ 10 at day 14.
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In various studies it has been shown that pro-inﬂammatory
cytokines, and in particular IFNg, directly stimulate the anti-
inﬂammatory capacity of ASCs31e33. First, we conﬁrmed that IFNg
could directly induce anti-inﬂammatory mediators arginase, IL-
1RA and iNOS in ASCs on mRNA level [Fig. 4(A)].IL-1b alsoFig. 2. Intra-articularly applied ASCs rapidly suppress synovial mRNA-expression of pro-inﬂa
7 of CIOA, and 6 h, 2, 14 and 42 days thereafter synovial RNA was collected. mRNA levels of a
(B) were measured on RT-qPCR and were signiﬁcantly lowered after 6 h (except for IL-6), how
42 days). * ¼ P < 0.05, ** ¼ P < 0.01 as measured by Student t test.induced higher levels of arginase and iNOS mRNA in ASCs, whereas
S100A8 did not affect any anti-inﬂammatory genes in ASCs
[Fig. 4(A)]. We next studied the in vitro effect of IL-1b and IFNg on
the cross talk between ASCs and activated macrophages. To do this,
murine bone marrow derived macrophages (BMM) were activated
with LPS and consequently stimulatedwith supernatant of IL-1b- or
IFNg-stimulated ASCs. The supernatant of IFNg-stimulated, but notmmatory mediators during collagenase-induced OA ASCs (20.000) were injected at day
larmins S100A8, A9 (A) and pro-inﬂammatory cytokines/chemokines IL-1b, IL-6 and KC
ever not at later timepoints. N ¼ 6-8 mice/group (2 synovia pooled at timepoints 2, 14,
Fig. 3. Intra-articular ASC-injection reduces synovial protein levels of pro-inﬂammatory S100A8/A9 and IL-1b during collagenase-induced OA ASCs (20.000) were injected at day 7
of CIOA, and 6 h, 2, 14 and 42 days thereafter synovial washouts were collected. Protein levels of S100A8/A9 were measured with a speciﬁc ELISA (A) and IL-1b, IL-6 and KC proteins
levels were measured on Luminex (B). S100A8/A9 levels were signiﬁcantly lowered 6 h and 2 days after ASC treatment, IL-1b at day 2, 14 and 42. C. TGFb-activity, measured by
CAGA-luc in synovial washouts, was not changed after ASC treatment. N ¼ 6 mice/group * ¼ P < 0.05, ** ¼ P < 0.01 as measured by Student t test.
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BMM (25-fold increase compared to unstimulated ASCs or IFNg
alone), while also upregulating iNOS (83- or 6-fold increase
compared to unstimulated ASCs or IFNg alone). Supernatant of
unstimulated ASCs already upregulated arginase mRNA levels in
BMM (8-fold increase). No effect was found on IL-1RA, IL-10 and
TGFb mRNA levels [Fig. 4(B)].
The efﬁcacy of local ASC treatment in the early phase of OA is related
to synovial thickness and is reﬂected by S100A8/A9 levels in the
serum
To investigatewhether the efﬁcacy of ASC treatment is related to
synovial thickness, we compared CIOA with high and somewhat
lower synovial inﬂammation by injecting 1U collagenase eitherFig. 4. Cytokine stimulated ASCs induce anti-inﬂammatory effects in activated macrophages
supernatants were used to stimulate activated murine bone-marrow derived macrophages
inﬂammatory mediators by ASCs, showing upregulation of arginase, IDO, IL-1RA and iNOS
while supernatant of IFNg-stimulated ASCs upregulated IDO and iNOS mRNA. IL-1RA, IL-10
corrected for GAPDH and unstimulated. Values in B are represented as eDCt, corrected fo
** ¼ P < 0.01, *** ¼ P < 0.005 as measured by Student t test.once or twice. The synovial thickening of CIOA on day 42 with one
time injectionwas 65% lower compared to two times injection (2.48
vs 1.5). However, this is still higher than observed in the DMM
model (synovial activation score at endpoint, day 56: 0.7, data not
shown). In the experiment with high synovial activation, day 7 ASC
treatment signiﬁcantly suppressed synovial thickening (32%
lower). In addition, osteophyte size was also greatly reduced in the
ASC treated group (72% lower) [Fig. 5(A)]. In contrast, in the CIOA
experiment with low synovial inﬂammation, no suppressive effect
of ASC treatment on synovial thickening, nor on osteophyte size
[Fig. 5(B)] was found. These data suggest that the inﬂammatory
status of the synovium drives the anti-inﬂammatory capacity of the
ASC.
During synovitis release of high amounts of pro-inﬂammatory
and catabolic S100A8/A9 may leak from the joint into theASCs were stimulated with pro-inﬂammatory cytokines IFNg, IL-1b and S100A8 and the
(BMM). A. Direct effects of IFNg, IL-1b and S100A8 on the mRNA expression of anti-
. B. Supernatants of unstimulated ASCs already upregulated arginase mRNA in BMM,
and TGFb mRNA levels in BMM were not affected. Values in A are represented as DDCt,
r GAPDH. Results are representative of two independent experiments. * ¼ P < 0.05,
Fig. 5. The efﬁcacy of local ASC treatment in the early phase of collagenase-induced OA depends on synovial activation. Two collagenase-induced OA experiments differing in
synovial thickening/activation (1.7 fold difference) at day 42 were compared on the effect of intra-articular ASC treatment at day 7. Local ASC treatment only reduces synovial
activation and osteophyte formation at the medial femur in OAwith high synovial activation (A), compared to OA with low synovial activation (B). Right panels show representative
histological pictures of hematoxylin-eosin stained knee sections (synovial activation, top panels) or Safranin-O stained knee sections on the medial side (osteophyte formation,
bottom panels). Magniﬁcation, 50 or 200, is indicated. * ¼ P-value <0.05, ** ¼ P-value<0.01. Signiﬁcance of osteophyte size was calculated using Student t test, synovial activation
with ManneWhitney U. n ¼ 6 mice/group.
R.F. Schelbergen et al. / Osteoarthritis and Cartilage 22 (2014) 1158e1166 1163bloodstream11. Serum was isolated at 14 and 42 days after ASC-
treatment in the two CIOA experiments differing in synovial acti-
vation. In the experiment with high synovial activation, serum
levels of S100A8/A9 levels were very high at day 14 (497 ng/ml,
371% of non-arthritic C57Bl6 mice, “naïve”) and at day 42 still
clearly above naïve (282 vs 134 ng/ml) [Fig. 6(A)]. In the experiment
showing less synovial thickening, serum levels of S100A8/A9 levels
were much lower at day 14 (272 vs 497 ng/ml) and returned to
control levels at day 42 [Fig. 6(B)]. Interestingly, in the ﬁrst exper-
iment, local application of ASC at day 7 after OA induction
dramatically inhibited S100A8/A9 serum levels (80% at day 14 and
44% at day 42 after treatment) [Fig. 6(A)]. In contrast, in the
experiment with low synovial activation, S100A8/A9 levels were
not signiﬁcantly changed by ASC treatment at day 14 whereas at
day 42 a 58% decrease was observed [Fig. 6(B)].Fig. 6. Efﬁcacy of ASC treatment can be measured by serum levels of S100A8/A9.
Systemic S100A8/A9 levels in collagenase-induced OA differing in synovial activation
was compared and the effect of ASC treatment at day 7 examined. A. Serum S100A8/A9
levels were very high in OA with higher synovial activation (807 ng/ml at day 14,
compared to 134 ng/ml in non-arthritic mice “naïve”) and were signiﬁcantly lowered
at day 14 and 42 when ASCs were given intra-articularly at day 7. B. In contrast,
S100A8/A9 serum levels were much lower in the experiment with low synovial acti-
vation (272 vs 807 ng/ml at day 14). Treatment with ASCs did not signiﬁcantly decrease
S100A8/A9 levels at day 14, only at day 42. S100A8/A9 was measured using ELISA.
n ¼ 8 mice/group, except naive (n ¼ 32) * ¼ P < 0.05, ** ¼ P < 0.01 as measured by
Student t test.Discussion
In the present study we ﬁnd that synovitis is essential in
mediating the immunosuppressive effects of ASCs in experimental
OA. S100A8/A9, as marker of this synovitis, could be used as pre-
dictor for successful ASC-treatment. Furthermore, locally adminis-
tered ASCs rapidly suppress the activation status of the synovial
lining layer possibly via a suppressive effect on macrophages.
Thickening of the synovial lining layer is a characteristic feature
of CIOA, paralleling large subgroups of OA patients that show sy-
novitis1. The synovial layer comprises mainly activated macro-
phages and selective elimination of these macrophages prior to
induction of CIOA strongly inhibited synovial thickening, chon-
drogenesis/osteophyte formation and cartilage destruction8. How-
ever, elimination of lining macrophages in destabilization of the
medial meniscus (DMM), in which synovitis is scant, has no effect
on OA pathology. In the present study we ﬁnd that when ASCs were
injected into a DMM OA joint, no effect was found on development
of joint destruction. Furthermore, ASC treatment is most efﬁcient
when given in a CIOA with high, not low synovitis. These data
further support the importance of the activated synovial lining and
macrophages in mediating the anti-inﬂammatory ASC effect.
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levels of pro-inﬂammatory cytokines released by activated synovial
lining macrophages. During early phase CIOA, levels of IL-1b and
S100A8/A9 are strongly upregulated in the synovium11. In the
present study we ﬁnd that injection of ASCs into day 7 CIOA joints
caused a rapid downregulation of both IL-1b and S100A8/A9 levels
and this effect was prolongated up to day 42 after treatment (for IL-
1b). Also, ﬁve days after injection, no ASCs could be detected
anymore within the synovium (data not shown). Apparently, a
short pulse is sufﬁcient for giving a prolonged ameliorating effect.
An explanation may be that the ASC imprint on synovial macro-
phages may result in transformation into suppressive macrophages
producing lower amounts of IL-1b or S100A8/A9 cytokines.
Although we show clear anti-inﬂammatory effects of ASCs in
CIOA, we cannot rule out that cell-types other than MSCs could
also induce immunomodulatory capacities. Indeed, we have
shown earlier that skin ﬁbroblasts exert anti-inﬂammatory ef-
fects in collagen-induced arthritis34. However, we believe that
the use of ASCs is superior to other cell-types. First, they have the
ability to differentiate into cell-types that can contribute to joint
repair, such as chondrocytes and osteoblasts15. Furthermore,
ASCs have an advantage of use in OA compared to ﬁbroblasts,
because the anti-inﬂammatory effect of the latter is largely
attributed to inhibition of T-cell proliferation and activation with
T-cells playing no role in OA pathogenesis. Finally, MSCs, to
which ASCs belong, are known for their low immunogenicity and
can be easily used in therapeutic approaches, without the need
of autologous application35.
It is becoming increasingly accepted that MSCs secrete many
factors including growth factors, cytokines, chemokines, metabo-
lites and bioactive lipids which orchestrate multiple interactions
with the surrounding microenvironment36. Pro-inﬂammatory cy-
tokines, like IFNg, IL-6, TNF-a and DAMPs, present during the ﬁrst
phase of CIOA, are capable of inducing an immunosuppressive
phenotype in ASCs/MSCs17,19,20,32. In reaction to these stimuli, ASCs
release factors like IDO, cyclo-oxygenase (COX)-2 and PGE2 which
are able to suppress activated macrophages, although subtle spe-
cies differences exist between mouse and man17,37. In line with that
we show that ASCs are able to induce expression of anti-
inﬂammatory mediators arginase and iNOS after IL-1b or IFNg
stimulation and upregulate IL-1RA after IFNg stimulation. More-
over, several in vitro and in vivo studies suggest that MSCs can
decrease inﬂammation by changing the macrophage phenotype
fromM1 (classically activated) to M2 (alternatively activated)38e40.
Previously, we already found that ASCs, when injected into the
knee joint, interact with synovial lining macrophages23. We now
ﬁnd that supernatant of IFNg stimulated ASC strongly upregulated
arginase, IDO and iNOS in activated macrophages which is char-
acteristic for transformation into an M2 signature. We speculate
that both IL-1b and IFNg could stimulate ASCs in vivo during
(experimental) OA, thereby activating their anti-inﬂammatory
phenotype, possibly via macrophages. IL-1b is frequently studied
and detected in OA synovium41,42. Although data on IFNg in OA is
more scarce, it has been shown to be present in OA synovium by
immunohistochemistry41,43 and IFNg positive CD4 T-cells were
found in OA synovium44,45. Finally, IFNg (and to a lesser extent IL-
1b) could also be used as tool to activate the ASCs ex vivo to
generate a larger anti-inﬂammatory potential.
Chondrogenesis within collateral/cruciate ligaments hampers a
good functioning of the joint and may further enhance cartilage
destruction. In previous studies performed in CIOA, we showed that
activated synovial macrophages mediate chondrogenesis/osteo-
phyte formation9,46. Macrophage derived factors involved in new
cartilage formation include growth factors like TGFb and BMP-29,47.
Production of these growth factors within the synovium wasstrongly diminished after macrophages were selectively depleted
from the lining layer46. However, ASC treatment did not suppress
mRNA levels of TGFb and BMPs or active TGFbwithin the synovium,
suggesting that ASCs mostly act via inhibition of pro-inﬂammatory
cytokines (IL-1b) or alarmins S100A8/A9, rather than via growth
factors.
Comparing efﬁcacy of ASC treatment in two CIOA experiments
differing in synovial activation we found that ASC treatment was
anti-inﬂammatory particularly when injected in joints with high
but not with low synovitis, indicating that a certain threshold of
pro-inﬂammatory factors is needed for induction of the anti-
inﬂammatory effect of ASCs. In line with this is that ASC treat-
ment when given at later phases (day 14 or day 21) after CIOA is
also not effective23 and that treatment of DMM with ASCs is also
ineffective [Fig. 1]. High synovial activation in CIOA joints was re-
ﬂected by high S100A8/A9 levels in the serum [Fig. 6]. S100A8/A9
produced in the synovium could leak out of the joint cavity thereby
reﬂecting inﬂammatory status in the serum48. S100A8/A9 serum
levels may thus be used ﬁrstly as a marker for determining syno-
vitis which is a licensing signal for using local ASC treatment.
Secondly, local stem cell treatment of CIOA joints lowered levels of
S100A8/A9 levels within the serum and may therefore also be used
as a marker for measuring the efﬁcacy of ASC treatment.
In the present paper we show that intra-articular deposition of
ASCs inhibit thickening/activation of the synovial lining layer and
protect joint destruction in experimental OA with high synovial
activation. ASCs had an immunomodulatory effect on the synovium
by suppressing catabolic factors like IL-1b and S100A8/A9 produced
by synovial macrophages. In vitro, ASCs upregulated anti-inﬂam-
matory factors in activated macrophages. Finally, S100A8/A9 could
be used both asmarker to determine feasibility of ASC-treatment in
experimental OA as well as read-out to determine its efﬁcacy.
ASCs may be a potent and safe tool to combat joint destruction
and inﬂammation in OA patients with high synovial activation.Author contributions
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